# Intratumoral PH-762 for Cutaneous Carcinoma

> **NCT06014086** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Phio Pharmaceuticals Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Skin
- Malignant Melanoma of Skin
- Merkel Cell Carcinoma of Skin

## Interventions

- **DRUG:** PH-762

## Key facts

- **NCT ID:** NCT06014086
- **Lead sponsor:** Phio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-07
- **Primary completion:** 2025-12-29
- **Final completion:** 2026-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014086, "Intratumoral PH-762 for Cutaneous Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06014086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*